360° SearchNetwork Hot Spots Trends Time Series

Avapro

Type: Product

Name: Avapro

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Sanofi Q1 net income decreases

Sanofi SA has reported that net income attributable to equity holders of the company for the first quarter of 2013 was E1.0 billion, or E0.76 per share, compared to E1.81 billion, or E1.37 per share, for the same quarter of 2012. Net sales for the first ... [Published Individual.com - May 15 2013]

Entities: Sanofi SA, Aubagio, Auvi-Q, Eloxatin, Christopher A Viehbacher

First reported May 14 2013 - Updated May 14 2013 - 1 reports

SANOFI: French Antitrust Authority Fines Sanofi EUR40.6 Million

PARIS--France's antitrust authority said Tuesday it has decided to fine French drugs giant Sanofi SA (SAN.FR) 40.6 million euros ($52.8 million) for what it called a "smear campaign" against certain generic drugs.In a statement, the authority said the ... [Published 4 Traders - May 14 2013]

Entities: Sanofi SA, Antitrust, Plavix, Nadya Masidlover, Drugs

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Lipitor

Income per script likely to hold this year

In the face of looming PBS price cuts the income per script should hold until 2014 with generic opportunities coming into the market place, a leading pharmacy business expert believes.Speaking at the PSA Offshore Refresher Conference 2013 in London, Bruce ... [Published Pharmacy News - May 10 2013]

Entities: Crestor, Lipitor, Drugs, Public Broadcasting Service

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Earnings Plummet, Outlook Maintained at Sanofi Zacks

Sanofi (SNY) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at constant exchange rates (:CER) from the year-ago period.First quarter ... [Published Yahoo! Finance - May 03 2013]

Entities: Sanofi SA, Avapro, Plavix, Fabrazyme

First reported May 02 2013 - Updated May 03 2013 - 4 reports

Sanofi profits drop by a third yet it insists patent cliff is over

Receive daily updates with our mid-morning newsletter PHARMACEUTICALS giant Sanofi yesterday assured investors that it is ready to bounce back with a range of new products, after patent expiries saw net profits plummet by 33.5 per cent in the first q ... [Published City A.M. - May 03 2013]

Entities: Sanofi SA, Patent, Diabetes, Eloxatin, Christopher Viehbacher

First reported May 02 2013 - Updated May 02 2013 - 3 reports

Sanofi's net profit drops by 45% to Euro 1,004 million in Q1

Sanofi has suffered heavy setback during the first quarter ended March 2013 on account of loss of exclusivity of its major product during 2012. Its net sales declined by 5.3 per cent to Euro 8,059 million from Euro 8,511 million in the similar period ... [Published PharmaBiz - May 02 2013]

Entities: Sanofi SA, Declination, Net Profit, Aprovel, Plavix

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Sanofi SA

Sanofi Gains As CEO Predicts Return To Topline Growth In H2

Sanofi (SNY) shares advanced more than 2% in pre-market trade after it reported worse than expected Q1 earnings, but its CEO Chris Viehbacher made a bullish call for the rest of the year, saying he expected revenue growth to resume in the second half. ... [Published Individual.com - May 02 2013]

Entities: Sanofi SA, Chris Viehbacher, Avapro

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

Bristol Myers Squibb Rating Reiterated by Zacks (BMY)

Bristol Myers Squibb (NYSE: BMY)Zacks' analyst wrote, "Bristol-Myers' first quarter 2013 adjusted earnings of $0.41 per share dipped 36% below the year-ago figure. Earnings were hurt primarily by the reduced sales of hypertension treatment Avapro/Avalide ... [Published American Banking News - Apr 27 2013]

Entities: Bristol-Myers Squibb Company, Avapro, Plavix, New York Stock Exchange

First reported Apr 26 2013 - Updated Apr 27 2013 - 2 reports

Bristol-Myers Squibb's New Drugs Can Help Reverse Its Sinking Revenue

Home » Blogs » Bristol Myers Squibb’s (BMY) Q1 results look like a letdown at first glance as the firm reported that its total sales for Q1 2013 were down almost 27% compared to the same quarter last year. However, much of this decline was expected as ... [Published BioPortfolio - Apr 27 2013]

Entities: Bristol-Myers Squibb Company, Avalide, Avapro, Drugs, Plavix

First reported Apr 25 2013 - Updated Apr 25 2013 - 4 reports

New Bristol-Myers drug growth cushions plummeting Plavix sales

Bristol-Myers Squibb ($BMY) chose a good day to report its first-quarter results. AstraZeneca's ($AZN) declining sales and profits help blunt its own disappointments: earnings that dropped 44%, on a 27% decline in sales. Fortunately, the $3.83 billion ... [Published FiercePharma - Apr 25 2013]

Entities: Bristol-Myers Squibb Company, Plavix, Avapro, Drugs

First reported Apr 25 2013 - Updated Apr 25 2013 - 4 reports

Bristol Myers Profit Declines on Expired Patents; Matches Earnings Estimates (BMY)

Biopharmaceutical company, Bristol Myers Squibb Co. ( BMY ) saw a decline in earnings on Thursday, caused by the loss of sales from expired patents. Still, the company matched analysts earnings estimates for the first quarter.The New York, NY based company ... [Published Dividend.com - Apr 25 2013]

Entities: Bristol-Myers Squibb Company, Avalide, Avapro

First reported Apr 25 2013 - Updated Apr 25 2013 - 4 reports

UPDATE: Bristol-Myers Profit Drops 45% on Lower Heart Drug Sales

--Bristol-Myers still feeling fallout from lost patent protection on Plavix --"Unremakable quarter" for Bristol-Myers, analyst says--Investors focused on pipeline, including key cancer treatment(Adds stock quote and analyst comment, beginning in paragraph ... [Published Capital.gr - Apr 25 2013]

Entities: Bristol-Myers Squibb Company, Drugs, Plavix

Quotes

...31 billion for the same quarter of 2012. Commenting on the Group's performance in Q1 2013, Sanofi CEO, Christopher A Viehbacher said, "As expected, the loss of exclusivity of Plavix, Avapro and Eloxatin in the course of 2012 in the US had a negative impact on Q1 results. However, our growth platforms continue to deliver strong results with diabetes, vaccines, and Genzyme all achieving double-digit growth. The early launch trends for Aubagio and Auvi-Q in the US are encouraging, regulatory approvals were granted for Lyxumia, Zaltrap and Hexyon in the EU, and we received positive CHMP opinion for Aubagio. Moreover, we look forward to the Phase III data releases for several pipeline projects later this year, including our new insulin glargine formulation and alirocumab. The Group expects to resume growth in the second half of 2"

Sanofi Q1 net income decreases [Published Individual.com - May 15 2013]

Commenting on the Group's performance in Q1 2013, Sanofi Chief Executive Officer, Christopher A Viehbacher said, "As expected, the loss of exclusivity of Plavix®, Avapro® and Eloxatin® in the course of 2012 in the U S had a negative impact on Q1 results."

1st Qtr: Sanofi Sales Down 2%, Net Income Drops 28% [Published Agri Marketing - May 06 2013]

The first three months of the year were "a milestone quarter for Sanofi", chief financial officer Jerome Contamine said in a televised interview. "It’s the last quarter we are seeing such a significant impact of the patent cliff."

Sanofi profit wilts under competition [Published BDlive - May 03 2013]

Chief executive Chris Viehbacher (pictured) was upbeat, saying Sanofi's growth platforms "continue to deliver strong results with diabetes, vaccines, and Genzyme all achieving double-digit growth" . He added that the early launch trends for the multiple sclerosis pill Aubagio (teriflunomide), which brought in 20 million euros, and Auvi-Q (epinephrine...

Sanofi profits plunge but forecasts strong second half [Published Pharma Times - May 02 2013]

More Content

sort by: Date \| Relevance
Bristol Myers: New Drugs Show Promise, Plavix P... [Published Trefis - May 17 2013]
3 Pharmaceuticals For Attractive Dividends [Published Seeking Alpha - May 15 2013]
Sanofi Q1 net income decreases [Published Individual.com - May 15 2013]
SANOFI: French Antitrust Authority Fines Sanofi... [Published 4 Traders - May 14 2013]
Buying the Pharma Dips [Published Motley Fool - May 13 2013]
Income per script likely to hold this year [Published Pharmacy News - May 10 2013]
1st Qtr: Sanofi Sales Down 2%, Net Income Drops... [Published Agri Marketing - May 06 2013]
Bristol-Myers Has The Future Of Oncology Therapies [Published Seeking Alpha - May 05 2013]
Earnings Plummet, Outlook Maintained at Sanofi ... [Published Yahoo! Finance - May 03 2013]
Sanofi profit wilts under competition [Published BDlive - May 03 2013]
Sanofi profits drop by a third yet it insists p... [Published City A.M. - May 03 2013]
Business briefs: Sanofi, Allergan, Otsuka, Genm... [Published Medical Marketing And Media - May 02 2013]
Sanofi Gains As CEO Predicts Return To Topline ... [Published Individual.com - May 02 2013]
Sanofi predicts return to growth in second half [Published PMLive - May 02 2013]
Sanofi profits plunge but forecasts strong seco... [Published Pharma Times - May 02 2013]
Sanofi's net profit drops by 45% to Euro 1,004 ... [Published PharmaBiz - May 02 2013]
Sanofi First-Quarter Profit Sinks 34%, More Tha... [Published Washington Post - May 02 2013]
Sanofi 1Q net drops 45 per cent as generic comp... [Published Okotoks Western Wheel - May 02 2013]
Sanofi Forecasts Second-Half Growth [Published 4 Traders - May 02 2013]
Sanofi earnings slashed in first quarter [Published Silver City Sun-News - May 02 2013]
Sanofi Q1 Profit Drops On Generic Competition; ... [Published RTTNews.com - May 02 2013]
Sanofi First-Quarter Profit Plunges 34%, Hurt b... [Published Bloomberg - May 02 2013]
Bristol Myers Squibb Rating Reiterated by Zacks... [Published American Banking News - Apr 27 2013]
Bristol-Myers Squibb's New Drugs Can Help Rever... [Published BioPortfolio - Apr 27 2013]
Bristol-Myers Squibb's New Drugs Can Help Rever... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 26 2013]
Bristol-Myers Squibb's Management Discusses Q1 ... [Published Seeking Alpha - Apr 26 2013]
New Bristol-Myers drug growth cushions plummeti... [Published FiercePharma - Apr 25 2013]
Bristol Myers Profit Declines on Expired Patent... [Published Dividend.com - Apr 25 2013]
Bristol-Myers Reports In Line Earnings - Analys... [Published Zacks.com - Apr 25 2013]
MARKET PULSE-ExxonMobil, 3M, United Parcel, Aka... [Published CNBC - Apr 25 2013]

Blogs

sort by: Date \| Relevance
Study: Minorities less exposed to some antihype... [Published Medad Blog - Mar 15 2013] By Mia Burns A study that was published in the February issue of the American Journal of Hypertension found that blacks, Latinos, and other ethnic minority hypertensive patients who are on dialysis were about 25 percent less likely to have exposure ...
AVAPRO (Irbesartan) Tablet [Bryant Ranch Prepack] [Published DailyMed Drug Label Updates for the last seven ... - Feb 21 2013] Updated Date: Feb 21, 2013 EST ...
AVAPRO (Irbesartan) Tablet [Bryant Ranch Prepack] [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2013] Updated Date: Feb 8, 2013 EST ...
AVAPRO (Irbesartan) Tablet [Bryant Ranch Prepack] [Published DailyMed Drug Label Updates for the last seven ... - Feb 08 2013] Updated Date: Feb 8, 2013 EST ...
AVAPRO (Irbesartan) Tablet [Sanofi-Aventis U.S.... [Published DailyMed Drug Label Updates for the last seven ... - Jan 16 2013] Updated Date: Jan 9, 2013 EST ...

Press Releases

sort by: Date \| Relevance
Mylan Launches Generic Avapro® Tablets and Gene... [Published PR Newswire - Sep 28 2012]